Status
Conditions
Treatments
About
There has been increasing use of venoarterial (VA) extracorporeal membrane oxygenation (ECMO) for infants with respiratory failure, up to 92% of neonatal respiratory support in 2021. This study seeks to leverage the increased use of VA ECMO in this cohort to enrich an evaluation of the differences in rate of intracranial hemorrhage and ischemic stroke between venovenous (VV) and VA ECMO among infants with respiratory failure where clinicians may choose either strategy.
This project is a retrospective review of data in the ELSO registry.
Full description
From 2019-2021, there was increased use of venoarterial (VA) extracorporeal membrane oxygenation (ECMO) for infants with respiratory failure, up to 92% of neonatal respiratory support in 2021. The primary aim is to estimate the average effect on the rate of neurologic injury of VA ECMO versus venovenous (VV) among infants with respiratory failure over the period 2013-2018, during which clinicians could choose either cannulation strategy. This causal effect will be estimated using an inverse propensity weighted (IPW) approach. Secondarily, the investigators will project this estimated treatment effect forward into the period 2019-2021. The beginning of this period roughly corresponds to start of increased use of VA ECMO. Under the assumption of a homogenous treatment effect across both study periods, the rate of neurologic injury that would have occurred in 2019-2021 will be estimated, had the rate of VA ECMO not increased relative to pre-2019 levels. The hypothesis is that the results will point to an increased rate of neurologic injury starting in 2019 due to the increased use of VA ECMO.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Patient had CDH
Patient was post-cardiotomy
Non-conventional initial cannulation strategies were employed, such as
Patient was transported into or out of ELSO center on ECMO support
Patient had pre-ECLS Cardiac Arrest
Patient did not have subsequent ECMO runs in the ELSO registry
5,058 participants in 2 patient groups
Loading...
Central trial contact
Joseph G Kohne; Ryan P Barbaro
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal